Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | GPX4 | P36969 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.47 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 3/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144687 | 0.91 | AR (0.46) | MAPK14MAPTMAP4K4PIM1GPX4 | |
| SCHEMBL4142870 | 0.88 | AR (0.46) | MAPK14MAPTPARP1ARCNR1 | |
| SCHEMBL4146511 | 0.83 | LMNA (0.44) | ARMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4148107 | 0.82 | HPGD (0.47) | ARHTTKIF11KDM4EMEN1 | |
| SCHEMBL4146476 | 0.81 | CSNK1D (0.41) | MAPTARHTTKIF11KDM4E | |
| SCHEMBL4144971 | 0.79 | MEN1 (0.42) | MAPTARCNR1HTTKDM4E | |
| SCHEMBL4145440 | 0.78 | TNKS2 (0.47) | MAPK14MAPTARCYP1A2TNKS | |
| SCHEMBL4143949 | 0.78 | LMNA (0.46) | MAPTGSK3BARKDM4EMEN1 | |
| SCHEMBL9949897 | 0.77 | PGR (0.46) | MAPTGSK3BDRD2HTR2AHTR2C | |
| SCHEMBL4139896 | 0.77 | AR (0.64) | MAPK14MAPTMAP4K4PIM1GPX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891067-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8580811-B2 | Androgen receptor modulator methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | MAPK14 3562/4885MAPT 4308/4885MAP4K4 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.